Clinical guidance of pyoderma gangrenosum 2022
- PMID: 37311717
- DOI: 10.1111/1346-8138.16845
Clinical guidance of pyoderma gangrenosum 2022
Abstract
Pyoderma gangrenosum (PG) is a rare, neutrophilic skin disease. For the purpose of accurate diagnosis and proper treatment of PG, the Japanese clinical practice guidance for PG developed by the Japanese Dermatological Association was published in 2022. In this guidance, clinical aspects, pathogenesis, current therapies, and clinical questions on PG are described from the viewpoints of current knowledge and evidence-based medicine. Here, the English version of the Japanese clinical practice guidelines for PG is presented and is intended to be widely referred to in the clinical examination and treatment of PG.
Keywords: Japanese guidance; neutrophilic disease; pyoderma gangrenosum.
© 2023 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
References
REFERENCES
- 
    - Yamamoto T, Yamasaki K, Yamanaka K, Oka M, Komine M. Guidance on the use of adalimumab in pyoderma gangrenosum. J Dermatol. 2021;131:479-89.
 
- 
    - Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderm (ecthyma) gangrenosum, clinical and experimental observations in five cases occurring in adults. Arch Derm Syphilol. 1930;22:655-80.
 
- 
    - Nishioka K. Pyoderma gangrenosum, classics of dermatology. Tokyo: A.M.S.; 2018. p. 194-9.
 
- 
    - Oka M. Clinical and pathological aspects of pyoderma gangrenosum. Rinsho Derma. 2018;60:1069-77.
 
- 
    - Yamamoto T. Pyoderma gangrenosum Update. J Dermatol. 2020;130:1439-48.
 
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
 
        